Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 598,943 shares, a decrease of 23.2% from the August 31st total of 779,902 shares. Approximately 5.2% of the shares of the company are short sold. Based on an average daily volume of 178,063 shares, the days-to-cover ratio is currently 3.4 days.

In other Syros Pharmaceuticals news, Director Richard A. Young sold 3,282 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $22.09, for a total value of $72,499.38. Following the sale, the director now directly owns 423,383 shares of the company’s stock, valued at $9,352,530.47. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric R. Olson sold 12,500 shares of the company’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $21.85, for a total transaction of $273,125.00. Following the completion of the sale, the insider now directly owns 12,500 shares in the company, valued at $273,125. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 21,564 shares of company stock worth $476,803. 33.60% of the stock is owned by corporate insiders.

A number of institutional investors have recently modified their holdings of the business. AWM Investment Company Inc. boosted its holdings in shares of Syros Pharmaceuticals by 155.8% in the second quarter. AWM Investment Company Inc. now owns 121,624 shares of the company’s stock valued at $1,957,000 after acquiring an additional 74,074 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Syros Pharmaceuticals by 131.3% in the second quarter. California State Teachers Retirement System now owns 22,200 shares of the company’s stock valued at $357,000 after acquiring an additional 12,600 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Syros Pharmaceuticals by 11,253.8% in the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock valued at $170,000 after acquiring an additional 10,466 shares in the last quarter. Redmile Group LLC boosted its holdings in shares of Syros Pharmaceuticals by 2.2% in the second quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after acquiring an additional 20,520 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Syros Pharmaceuticals by 176.7% in the second quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after acquiring an additional 108,250 shares in the last quarter. 59.61% of the stock is currently owned by institutional investors.

Shares of Syros Pharmaceuticals (NASDAQ:SYRS) opened at 16.58 on Friday. The firm has a 50-day moving average of $15.76 and a 200 day moving average of $15.76. Syros Pharmaceuticals has a 12-month low of $10.22 and a 12-month high of $17.89. The stock’s market capitalization is $435.39 million.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Equities analysts forecast that Syros Pharmaceuticals will post ($2.09) earnings per share for the current fiscal year.

SYRS has been the topic of several recent research reports. Cann reaffirmed a “buy” rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a report on Monday, August 21st. Oppenheimer Holdings, Inc. set a $28.00 price target on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a report on Monday, June 12th. Cowen and Company reaffirmed a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, ValuEngine raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. Syros Pharmaceuticals has a consensus rating of “Buy” and an average target price of $26.37.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/10/06/short-interest-in-syros-pharmaceuticals-inc-syrs-drops-by-23-2.html.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Stock Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.